Abacavir pharmacogenomics
Tools
Tools
Phillips, E.J. and Mallal, S. (2014) Abacavir pharmacogenomics. In: Murray, M.F., Babyatsky, M.W., Giovanni, M.A., Alkuraya, F.S. and Stewart, D.S., (eds.) Clinical Genomics: Practical Applications in Adult Patient Care. McGraw-Hill Professional.
*Open access. Some pages may not be available
Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy for the treatment of the human immunodeficiency virus type 1 (HIV-1) that has been associated with a hypersensitivity reaction in approximately 8% of those starting the drug.
Abacavir hypersensitivity reaction is characterized by greater than or equal to two progressive symptoms typically starting from the second week of therapy (median 9 days) with fever, malaise, nausea, vomiting, diarrhea, and later mild-to-moderate skin rash (present in 70% of patients).
Symptoms of abacavir hypersensitivity resolve rapidly with 24 to 72 hours after drug discontinuation.
A previous clinical history compatible with abacavir hypersensitivity is a contraindication to future rechallenge as severe morbidity and even mortality characterized by hypotension and shock has been described.
| Item Type: | Book Chapter |
|---|---|
| Murdoch Affiliation: | Institute for Immunology and Infectious Diseases |
| Publisher: | McGraw-Hill Professional |
| Copyright: | © 2014 by McGraw-Hill Education |
| URI: | http://researchrepository.murdoch.edu.au/id/eprint/39673 |
 |
Item Control Page |
